

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Report and Forecast 2023-2031

Market Report | 2023-04-10 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Report and Forecast 2023-2031

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Outlook

The global adeno-associated virus (AAV) vector-based gene therapy market is expected to witness significant growth during the forecast period of 2023-2031, driven by the rising prevalence of genetic disorders and the increasing investments in research and development activities. The market is projected to grow at a CAGR of 18.5% during the forecast period.

Adeno-Associated Virus Vector-Based Gene Therapy Market: Introduction

The global adeno-associated virus (AAV) vector-based gene therapy market report by Expert Market Research provides an in-depth analysis of the market and its segments. AAV is a non-pathogenic virus that is used as a delivery vehicle for therapeutic genes to treat genetic disorders. The report covers the market for AAV vector-based gene therapy and provides a detailed analysis of the market size, growth, and trends.

The AAV vector-based gene therapy market is expected to witness significant growth in the coming years due to the increasing prevalence of genetic disorders and the rising demand for innovative treatment options. The development of advanced technologies, such as genome editing and gene silencing, is expected to further drive the growth of the market. Additionally, the increasing focus on precision medicine and personalized treatment options is likely to create lucrative opportunities for the market players.

Furthermore, the increasing investments in research and development activities, coupled with the growing number of clinical trials, are expected to fuel the growth of the market. The adoption of advanced healthcare infrastructure and the increasing demand for better healthcare services in emerging economies are expected to further contribute to the growth of the market.

Adeno-Associated Virus Vector-Based Gene Therapy Market Segmentations

The market can be categorised into therapeutic agents, indication type, and treatment channel.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Market Breakup by Therapeutic Agents

- Corticosteroid Drugs
- Immunosuppressive Drugs
- ACE Inhibitors and ARBs
- Others

Market Breakup by Indication Type

- Haematological Disorders
 - o□Haemophilia A
 - o□Haemophilia B
- Ophthalmological Disorders
 - o□Chloridaemia
 - o□Retinitis Pigmentosa
- Lysosomal Storage Disorders
 - o□Fabry Disease
 - o□Pompe Disease
 - o□Hunter Syndrome
- Neurological Disorders
 - o□Parkinson's Disease
 - o□Batten Disease
- Musculoskeletal Disorders
 - o□Duchenne Muscular Dystrophy (DMD)
 - o□Spinal Muscular Atrophy (SMA)

Market Breakup by Treatment Channel

- Public
- Private

Market Breakup by Region

- North America
 - ?□United States of America
 - ?□Canada
- Europe
 - ?□United Kingdom
 - ?□Germany
 - ?□France
 - ?□Italy
 - ?□Others
- Asia Pacific
 - ?□China
 - ?□Japan
 - ?□India
 - ?□ASEAN
 - ?□Australia
 - ?□Others
- Latin America
 - ?□Brazil
 - ?□Argentina
 - ?□Mexico
 - ?□Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Middle East and Africa
- ?□ Saudi Arabia
- ?□ United Arab Emirates
- ?□ Nigeria
- ?□ South Africa
- ?□ Others

Adeno-Associated Virus Vector-Based Gene Therapy Market Scenario

The global adeno -Associated Virus (AAV) vector-based gene therapy market is expected to witness significant growth during the forecast period of 2023-2031. North America dominates the market, followed by Europe and Asia Pacific. The high prevalence of genetic disorders in North America, coupled with the favorable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for AAV vector-based gene therapy, with the presence of key players and increasing investments in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of genetic disorders and rising healthcare expenditure in the region.

Key Players in the Global Adeno-Associated Virus Vector-Based Gene Therapy Market

The report gives an in-depth analysis of the key players involved in the adeno-associated virus vector-based gene therapy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- Arya Sciences Acquisition Corp.
- Pfizer Inc.
- Roche Holding AG
- BioMarin Pharmaceutical Inc.
- Bayer AG
- Coave Therapeutics
- MeiraGTx Limited
- Neurocrine Biosciences, Inc.
- Biogen, Inc.
- Sangamo Therapeutics
- Sarepta Therapeutics, Inc.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
- 2 Research Methodology
- 3 Executive Summary
- 4 Adeno-Associated Virus Vector-Based Gene Therapy Overview
 - 4.1 Guidelines and Stages
 - 4.2 Pathophysiology
 - 4.3 Screening and Diagnosis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.4 Treatment Pathway
- 5 Patient Profile
 - 5.1 Patient Profile Overview
 - 5.2 Patient Psychology and Emotional Impact Factors
 - 5.3 Risk Assessment and Treatment Success Rate
- 6 Current Scenario Evaluation and Regulatory Framework
 - 6.1 Emerging Therapies and Clinical Trials
 - 6.2 Patent Landscape
 - 6.2.1 Patent Overview
 - 6.2.1.1 Patent Status and Expiry
 - 6.2.1.2 Timelines from Drug Development to Commercial Launch
 - 6.2.1.3 New Drug Application
 - 6.2.1.3.1 Documentation and Approval Process
 - 6.3 Cost of Treatment
 - 6.4 Regulatory Framework
 - 6.4.1 Regulatory Overview
 - 6.4.1.1 US FDA
 - 6.4.1.2 EU EMA
 - 6.4.1.3 INDIA CDSCO
 - 6.4.1.4 JAPAN PMDA
 - 6.4.1.5 Others
- 7 Challenges and Unmet Needs
 - 7.1 Treatment Pathway Challenges
 - 7.2 Compliance and Drop-Out Analysis
 - 7.3 Awareness and Prevention Gaps
- 8 Global Adeno-Associated Virus Vector-Based Gene Therapy Market
 - 8.1 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Overview
 - 8.2 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Analysis
 - 8.2.1 Market Overview
 - 8.2.1.1 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Historical Value (2016-2022)
 - 8.2.1.2 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Forecast Value (2023-2031)
 - 8.3 Global Adeno-Associated Virus Vector-Based Gene Therapy Market by Therapeutic Agents
 - 8.3.1 Market Overview
 - 8.3.1.1 Corticosteroid Drugs
 - 8.3.1.2 Immunosuppressive Drugs
 - 8.3.1.3 ACE Inhibitors and ARBs
 - 8.3.1.4 Others
 - 8.4 Global Adeno-Associated Virus Vector-Based Gene Therapy Market by Indication Type
 - 8.4.1 Market Overview
 - 8.4.1.1 Hematological Disorders
 - 8.4.1.1.1 Hemophilia A
 - 8.4.1.1.2 Hemophilia B
 - 8.4.1.2 Ophthalmological Disorders
 - 8.4.1.2.1 Choroideremia
 - 8.4.1.2.2 Retinitis Pigmentosa
 - 8.4.1.3 Lysosomal Storage Disorders
 - 8.4.1.3.1 Fabry Disease

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.4.1.3.2 Pompe Disease
 - 8.4.1.3.3 Hunter Syndrome
 - 8.4.1.4 Neurological Disorders
 - 8.4.1.4.1 Parkinson's Disease
 - 8.4.1.4.2 Batten Disease
 - 8.4.1.5 Musculoskeletal Disorders
 - 8.4.1.5.1 Duchenne Muscular Dystrophy (DMD)
 - 8.4.1.5.2 Spinal Muscular Atrophy (SMA)
- 8.5 Global Adeno-Associated Virus Vector-Based Gene Therapy Market by Treatment Channel
 - 8.5.1 Market Overview
 - 8.5.1.1 Public
 - 8.5.1.2 Private
- 8.6 Global Adeno-Associated Virus Vector-Based Gene Therapy Market by Region
 - 8.6.1 Market Overview
 - 8.6.1.1 North America
 - 8.6.1.2 Europe
 - 8.6.1.3 Asia Pacific
 - 8.6.1.4 Middle East and Africa
 - 8.6.1.5 Latin America
- 9 North America Adeno-Associated Virus Vector-Based Gene Therapy Market
 - 9.1 Market Share by Country
 - 9.2 United States of America
 - 9.2.1 Historical Trend (2016-2022)
 - 9.2.2 Forecast Trend (2023-2031)
 - 9.3 Canada
 - 9.3.1 Historical Trend (2016-2022)
 - 9.3.2 Forecast Trend (2023-2031)
- 10 Europe Adeno-Associated Virus Vector-Based Gene Therapy Market
 - 10.1 Market Share by Country
 - 10.2 United Kingdom
 - 10.2.1 Historical Trend (2016-2022)
 - 10.2.2 Forecast Trend (2023-2031)
 - 10.3 Germany
 - 10.3.1 Historical Trend (2016-2022)
 - 10.3.2 Forecast Trend (2023-2031)
 - 10.4 France
 - 10.4.1 Historical Trend (2016-2022)
 - 10.4.2 Forecast Trend (2023-2031)
 - 10.5 Italy
 - 10.5.1 Historical Trend (2016-2022)
 - 10.5.2 Forecast Trend (2023-2031)
 - 10.6 Others
- 11 Asia Pacific Adeno-Associated Virus Vector-Based Gene Therapy Market
 - 11.1 Market Share by Country
 - 11.2 China
 - 11.2.1 Historical Trend (2016-2022)
 - 11.2.2 Forecast Trend (2023-2031)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3 Japan
 - 11.3.1 Historical Trend (2016-2022)
 - 11.3.2 Forecast Trend (2023-2031)
- 11.4 India
 - 11.4.1 Historical Trend (2016-2022)
 - 11.4.2 Forecast Trend (2023-2031)
- 11.5 ASEAN
 - 11.5.1 Historical Trend (2016-2022)
 - 11.5.2 Forecast Trend (2023-2031)
- 11.6 Australia
 - 11.6.1 Historical Trend (2016-2022)
 - 11.6.2 Forecast Trend (2023-2031)
- 11.7 Others
- 12 Latin America Adeno-Associated Virus Vector-Based Gene Therapy Market
 - 12.1 Market Share by Country
 - 12.2 Brazil
 - 12.2.1 Historical Trend (2016-2022)
 - 12.2.2 Forecast Trend (2023-2031)
 - 12.3 Argentina
 - 12.3.1 Historical Trend (2016-2022)
 - 12.3.2 Forecast Trend (2023-2031)
 - 12.4 Mexico
 - 12.4.1 Historical Trend (2016-2022)
 - 12.4.2 Forecast Trend (2023-2031)
 - 12.5 Others
- 13 Middle East and Africa Adeno-Associated Virus Vector-Based Gene Therapy Market
 - 13.1 Market Share by Country
 - 13.2 Saudi Arabia
 - 13.2.1 Historical Trend (2016-2022)
 - 13.2.2 Forecast Trend (2023-2031)
 - 13.3 United Arab Emirates
 - 13.3.1 Historical Trend (2016-2022)
 - 13.3.2 Forecast Trend (2023-2031)
 - 13.4 Nigeria
 - 13.4.1 Historical Trend (2016-2022)
 - 13.4.2 Forecast Trend (2023-2031)
 - 13.5 South Africa
 - 13.5.1 Historical Trend (2016-2022)
 - 13.5.2 Forecast Trend (2023-2031)
 - 13.6 Others
- 14 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Dynamics
 - 14.1 Market Drivers and Constraints
 - 14.2 SWOT Analysis
 - 14.3 Porter's Five Forces Model
 - 14.4 Key Demand Indicators
 - 14.5 Key Price Indicators
 - 14.6 Industry Events, Initiatives & Trends

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.7 Value Chain Analysis
- 15 Supplier Landscape
 - 15.1 Arya Sciences Acquisition Corp.
 - 15.1.1 Company Overview
 - 15.1.2 Product Portfolio
 - 15.1.3 Demographic Reach and Achievements
 - 15.1.4 Mergers and Acquisitions
 - 15.1.5 Certifications
 - 15.2 Pfizer Inc.
 - 15.2.1 Company Overview
 - 15.2.2 Product Portfolio
 - 15.2.3 Demographic Reach and Achievements
 - 15.2.4 Mergers and Acquisitions
 - 15.2.5 Certifications
 - 15.3 Roche Holding AG
 - 15.3.1 Company Overview
 - 15.3.2 Product Portfolio
 - 15.3.3 Demographic Reach and Achievements
 - 15.3.4 Mergers and Acquisitions
 - 15.3.5 Certifications
 - 15.4 BioMarin Pharmaceutical Inc.
 - 15.4.1 Company Overview
 - 15.4.2 Product Portfolio
 - 15.4.3 Demographic Reach and Achievements
 - 15.4.4 Mergers and Acquisitions
 - 15.4.5 Certifications
 - 15.5 Bayer AG
 - 15.5.1 Company Overview
 - 15.5.2 Product Portfolio
 - 15.5.3 Demographic Reach and Achievements
 - 15.5.4 Mergers and Acquisitions
 - 15.5.5 Certifications
 - 15.6 Coave Therapeutics
 - 15.6.1 Company Overview
 - 15.6.2 Product Portfolio
 - 15.6.3 Demographic Reach and Achievements
 - 15.6.4 Mergers and Acquisitions
 - 15.6.5 Certifications
 - 15.7 MeiraGTx Limited
 - 15.7.1 Company Overview
 - 15.7.2 Product Portfolio
 - 15.7.3 Demographic Reach and Achievements
 - 15.7.4 Mergers and Acquisitions
 - 15.7.5 Certifications
 - 15.8 Neurocrine Biosciences, Inc.
 - 15.8.1 Company Overview
 - 15.8.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.8.3 Demographic Reach and Achievements
- 15.8.4 Mergers and Acquisitions
- 15.8.5 Certifications
- 15.9 Biogen, Inc.
 - 15.9.1 Company Overview
 - 15.9.2 Product Portfolio
 - 15.9.3 Demographic Reach and Achievements
 - 15.9.4 Mergers and Acquisitions
 - 15.9.5 Certifications
- 15.10 Sangamo Therapeutics
 - 15.10.1 Company Overview
 - 15.10.2 Product Portfolio
 - 15.10.3 Demographic Reach and Achievements
 - 15.10.4 Mergers and Acquisitions
 - 15.10.5 Certifications
- 15.11 Sarepta Therapeutics, Inc.
 - 15.11.1 Company Overview
 - 15.11.2 Product Portfolio
 - 15.11.3 Demographic Reach and Achievements
 - 15.11.4 Mergers and Acquisitions
 - 15.11.5 Certifications
- 16 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Distribution Model (Additional Insight)
 - 16.1 Overview
 - 16.2 Potential Distributors
 - 16.3 Key Parameters for Distribution Partner Assessment
- 17 Payment Methods (Additional Insight)
 - 17.1 Government Funded
 - 17.2 Private Insurance
 - 17.3 Out-of-Pocket

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Report and Forecast 2023-2031

Market Report | 2023-04-10 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com